Literature DB >> 34321527

Human chromosome 3p21.3 carries TERT transcriptional regulators in pancreatic cancer.

Takuki Yagyu1,2, Takahito Ohira2,3, Ryutaro Shimizu2,4, Masaki Morimoto1, Yuki Murakami1, Takehiko Hanaki1, Kyoichi Kihara1, Tomoyuki Matsunaga1, Manabu Yamamoto1, Naruo Tokuyasu1, Teruhisa Sakamoto1, Yoshiyuki Fujiwara1, Hiroyuki Kugoh5,6.   

Abstract

Frequent loss of heterozygosity (LOH) on the short arm of human chromosome 3 (3p) region has been found in pancreatic cancer (PC), which suggests the likely presence of tumor suppressor genes in this region. However, the functional significance of LOH in this region in the development of PC has not been clearly defined. The human telomerase reverse transcriptase gene (hTERT) contributes to unlimited proliferative and tumorigenicity of malignant tumors. We previously demonstrated that hTERT expression was suppressed by the introduction of human chromosome 3 in several cancer cell lines. To examine the functional role of putative TERT suppressor genes on chromosome 3 in PC, we introduced an intact human chromosome 3 into the human PK9 and murine LTPA PC cell lines using microcell-mediated chromosome transfer. PK9 microcell hybrids with an introduced human chromosome 3 showed significant morphological changes and rapid growth arrest. Intriguingly, microcell hybrid clones of LTPA cells with an introduced human chromosome 3 (LTPA#3) showed suppression of mTert transcription, cell proliferation, and invasion compared with LTPA#4 cells containing human chromosome 4 and parental LTPA cells. Additionally, the promoter activity of mTert was downregulated in LTPA#3. Furthermore, we confirmed that TERT regulatory gene(s) are present in the 3p21.3 region by transfer of truncated chromosomes at arbitrary regions. These results provide important information on the functional significance of the LOH at 3p for development and progression of PC.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34321527     DOI: 10.1038/s41598-021-94711-6

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  45 in total

Review 1.  Pancreatic cancer.

Authors:  Jonathan D Mizrahi; Rishi Surana; Juan W Valle; Rachna T Shroff
Journal:  Lancet       Date:  2020-06-27       Impact factor: 79.321

2.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

3.  Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays.

Authors:  Eric S Calhoun; Tomas Hucl; Eike Gallmeier; Kristen M West; Dan E Arking; Anirban Maitra; Christine A Iacobuzio-Donahue; Aravinda Chakravarti; Ralph H Hruban; Scott E Kern
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

Review 4.  Stromal reengineering to treat pancreas cancer.

Authors:  Ingunn M Stromnes; Kathleen E DelGiorno; Philip D Greenberg; Sunil R Hingorani
Journal:  Carcinogenesis       Date:  2014-06-07       Impact factor: 4.944

5.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

6.  Identification of FAP locus genes from chromosome 5q21.

Authors:  K W Kinzler; M C Nilbert; L K Su; B Vogelstein; T M Bryan; D B Levy; K J Smith; A C Preisinger; P Hedge; D McKechnie
Journal:  Science       Date:  1991-08-09       Impact factor: 47.728

7.  A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma.

Authors:  S H Friend; R Bernards; S Rogelj; R A Weinberg; J M Rapaport; D M Albert; T P Dryja
Journal:  Nature       Date:  1986 Oct 16-22       Impact factor: 49.962

Review 8.  Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers.

Authors:  Jane Antony; Elisa Zanini; James R Birtley; Hani Gabra; Chiara Recchi
Journal:  Cancer Gene Ther       Date:  2020-06-29       Impact factor: 5.987

9.  Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.

Authors:  Wanglong Qiu; Fikret Sahin; Christine A Iacobuzio-Donahue; Dario Garcia-Carracedo; Wendy M Wang; Chia-Yu Kuo; Doris Chen; Dan E Arking; Andrew M Lowy; Ralph H Hruban; Helen E Remotti; Gloria H Su
Journal:  Oncotarget       Date:  2011-11

Review 10.  Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods.

Authors:  Maria de Lourdes L F Chauffaille; Ilana Zalcberg; Wolney Gois Barreto; Israel Bendit
Journal:  Hematol Transfus Cell Ther       Date:  2020-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.